Vertex Pharmaceuticals in den Nachrichten
Entwicklung transformativer Medikamente
Tamtam hat 20 aktuelle Artikel über Vertex Pharmaceuticals gefunden.
- Has Vertex Stock Become A Different Bet?
- Vertex Pharmaceuticals falls 2.94% in Thursday's session
- 2 Growth Stocks to Buy in November Without Any Hesitation
- At $547.86 apiece, a director sold 271 Vertex Pharmaceuticals (VRTX) shares.
- Genomics and Vertex Extend $220 million Drug Discovery Partnership Deal
- After selling 1,000 shares of Vertex Pharmaceuticals (VRTX), Nancy Thornberry directly held 1,109.
- Vertex Pharmaceuticals stock gains EUR 485.85, up 0.65%
- Vertex Pharmaceuticals (VRTX) Stock May Be Undervalued After Its 187% Run
- Should You Pick Vertex Stock Over Its Biotech Rivals?
- VRTX Stock News Today: Latest Updates & Live Price | MEXC
- VRTX: Pivotal renal readouts and expanding non-CF revenue shape the 2027 outlook
- Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
- Vertex at Jefferies Global Healthcare Conference: kidney push builds
- Vertex Pharmaceuticals stock slips to EUR 487.60, down 1.28%
- Will Vertex Pharmaceuticals (NASDAQ:VRTX) Turn Its Pipeline Into Momentum?
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
- Director Sangeeta N. Bhatia proposes selling 271 Vertex Pharmaceuticals (VRTX) shares.
- Vertex Pharmaceuticals stock at EUR 492.55, up 1.10%
- Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
- Vertex Pharmaceuticals stock: Management's UBS conference appearance
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Vertex Pharmaceuticals?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden